Collegium Pharmaceutical (COLL) Revenue (2016 - 2026)

Collegium Pharmaceutical has reported Revenue for 11 years, with the latest figure at $199.9 million in Q2 2026.

• On a quarterly basis, Revenue rose 6.32% year-over-year to $199.9 million in Q2 2026; TTM through Jun 2026 was $808.2 million, a 14.31% increase from a year earlier, with the FY2025 full-year figure at $780.6 million, up 23.62% from the prior year.
• Revenue was $199.9 million for Q2 2026 at Collegium Pharmaceutical, up from $193.5 million in the prior quarter.
• The five-year high for Revenue was $209.4 million in Q3 2025, with the low at $83.8 million in Q1 2022.
• Average Revenue over 5 years is $158.2 million, with a median of $147.5 million recorded in 2023.
• The largest YoY upside for Revenue was 414.05% in 2022 against a maximum downside of 4.53% in 2022.
• Over 5 years, Revenue stood at $140.7 million in 2022, then gained by 6.46% to $149.7 million in 2023, then climbed by 21.51% to $181.9 million in 2024, then gained by 12.92% to $205.4 million in 2025, then decreased by 2.71% to $199.9 million in 2026.
• The last three Revenue figures came in at $199.9 million (Q2 2026), $193.5 million (Q1 2026), and $205.4 million (Q4 2025), per Business Quant data.